Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
Open Access
- 11 September 2007
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 56 (5) , 360-366
- https://doi.org/10.1016/j.phrs.2007.09.003
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- A biosynthetic pathway for anandamideProceedings of the National Academy of Sciences, 2006
- Modulation of Neuropathic and Inflammatory Pain by the Endocannabinoid Transport Inhibitor AM404 [N-(4-Hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]The Journal of Pharmacology and Experimental Therapeutics, 2006
- Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factorsExpert Opinion on Investigational Drugs, 2006
- Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effectsJournal of Clinical Investigation, 2005
- Identification and Functional Characterization of Brainstem Cannabinoid CB2ReceptorsScience, 2005
- Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?Behavioural Pharmacology, 2005
- Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampusNature Neuroscience, 2005
- Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victimsMolecular Psychiatry, 2004
- Isolation, Characterization, and Regulation of Diacylglycerol Lipases from the Bovine BrainAnnals of the New York Academy of Sciences, 1989
- Isolation, Structure, and Partial Synthesis of an Active Constituent of HashishJournal of the American Chemical Society, 1964